N Baiji (920201) Surges Over 388% on Beijing Stock Exchange Debut
N Baiji (stock code 920201), a biomedical materials company, debuted on the Beijing Stock Exchange on September 24, 2026, opening at 75.00 yuan, a 347.23% surge from its IPO price of 16.77 yuan. By the morning close, gains reached 388.13%, with a half-day turnover of 482 million yuan. The IPO was heavily oversubscribed, with an allocation rate of 0.01%. The company reported net profits of 50.08 million yuan (2023), 52.31 million yuan (2024), and 76.34 million yuan (2025).
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- N Baiji is a legitimate 'specialized and new' biomedical company with real technology and strategic importance for China.
- The Beijing Stock Exchange was deliberately designed to serve innovative SMEs and align with national development priorities.
- Western markets have their own significant problems, like SPAC implosions and meme stock frenzies.
- Market mechanisms always reflect political choices and are never neutral.
Points of contention
- Eastern Agent sees the 347% first-day pop as a strategic feature that signals confidence and attracts listings, while Neutral Agent views it as a structural pricing failure that leaves money on the table.
- Eastern Agent argues the 0.01% allocation rate enables broad participation through market-wide signals, while Neutral Agent calls it a lottery that benefits only insiders and flippers.
- Eastern Agent believes the aftermarket valuation helps the company through secondary offerings and equity compensation, while Neutral Agent says the value is captured by day traders, not patient capital.
- Eastern Agent frames the system as sovereign financial innovation suited to a multipolar world, while Neutral Agent calls it rent-seeking disguised as strategy.
Blind spots
- Neither side fully addresses whether the extreme oversubscription actually leads to higher long-term R&D spending or better innovation outcomes for listed companies.
- Both agents overlook the potential for regulatory changes to gradually reduce underpricing as the Beijing Stock Exchange matures.
- The debate ignores how retail investors who don't get allocations might lose trust in the market over time.
WorldAttention’s read
The roundtable revealed a fundamental clash between two worldviews: Eastern Agent sees the Beijing Stock Exchange's IPO mechanism as a deliberate, strategic tool that prioritizes long-term industrial goals and market confidence over short-term pricing efficiency, while Neutral Agent argues it's a structurally flawed system that systematically underprices IPOs, creating artificial scarcity and transferring wealth from companies to flippers. Both agree N Baiji is a legitimate tech company and that Western markets have their own failures, but they disagree sharply on whether a 347% first-day pop is a feature or a bug. The key blind spot is the lack of data on whether this system actually boosts long-term innovation for SMEs, and both sides could benefit from examining how the mechanism might evolve over time.
Reporting timeline
Beijing Stock Exchange New Stock N Bairuiji Surges 388.13% at Morning Close on Debut
N Bairuiji (stock code 920201), a new stock on the Beijing Stock Exchange, surged 388.13% by the morning close on its first trading day, expanding from an opening gain of 347.23%. The stock saw a half-day trading volume of 5.7464 million shares, with a turnover of 482 million yuan and a turnover rate of 75.53%. According to Securities Times data, the company is primarily engaged in the research, development, production, and sales of biomedical materials. Its net profits for 2023, 2024, and 2025 were 50.0784 million yuan, 52.3116 million yuan, and 76.3401 million yuan, respectively. The company issued 8.2258 million shares at an issue price of 16.77 yuan, with a price-to-earnings ratio of 14.99 times. Strategic placement shares totaled 822,600 shares, accounting for 10% of the initial issuance. The online offering saw an effective subscription volume of 51,000,517,700 shares, with an effective subscription multiple of 6,888.94 times and 714,300 valid subscribers, resulting in an online allocation rate of 0.01%. The report notes this is news and not investment advice.
Read sourceN Baiji Surges Over 470% on Beijing Stock Exchange Debut, Hits 97 Yuan
On September 24, N Baiji (stock code 920201) surged on its debut on the Beijing Stock Exchange, opening sharply higher and rising over 478% to a high of 97 yuan per share. As of reporting, the stock had eased to 88.79 yuan, still up over 420%, giving it a market capitalization of 6.1 billion yuan with a turnover of 375 million yuan. N Baiji is a national-level specialized and new 'little giant' enterprise engaged in the R&D, production, and sales of biomedical materials, particularly for post-surgical tissue repair and anti-adhesion in gynecological procedures. The company reported revenues of 198 million yuan, 231 million yuan, and 284 million yuan for 2023, 2024, and 2025 respectively, with net profits of 50 million yuan, 52 million yuan, and 76 million yuan. It forecasts revenue of 230 million to 250 million yuan for the first nine months of 2026, representing year-on-year growth of 14.98% to 24.98%, and net profit of 60 million to 65 million yuan, up 5.29% to 15.03%.
Read sourceN Baorui Ji Debuts on Beijing Stock Exchange, Opens Up 347.23%
N Baorui Ji (stock code 920201) began trading on the Beijing Stock Exchange on September 24, 2026, with an opening price of 75.00 yuan, representing a surge of 347.23% above its initial public offering price of 16.77 yuan. The company specializes in the research, development, production, and sales of biomedical materials. Its listing application was accepted by the Beijing Stock Exchange on December 26, 2024, and the entire process from acceptance to listing took 637 days. According to data from Securities Times, the company issued 8.2258 million shares publicly, with a price-to-earnings ratio of 14.99 times. Strategic placement shares accounted for 10% of the initial offering. The online offering saw massive demand, with valid subscriptions totaling 51,000,517,700 shares, an oversubscription ratio of 6,888.94 times, and a final allotment ratio of just 0.01%. The company reported net profits of 50.0784 million yuan, 52.3116 million yuan, and 76.3401 million yuan for the years 2023, 2024, and 2025, respectively. The article also includes a table comparing recent Beijing Stock Exchange new listings by their first-day opening performance.
Read sourceShow 2 older updatesHide older updates
Beijing Stock Exchange Newcomer N Bairuiji Surges 388% in Morning Trading Debut
N Bairuiji (stock code 920201), a new stock on the Beijing Stock Exchange (BSE), made a strong debut on its first trading day. The stock opened with a gain of 347.23% and extended its rally to 388.13% by the morning close. During the half-day session, 5.7464 million shares were traded, generating a turnover of 482 million yuan, with a turnover rate of 75.53%. The company specializes in the research, development, production, and sale of biomedical materials. According to data from Securities Times, the company reported net profits of 50.0784 million yuan, 52.3116 million yuan, and 76.3401 million yuan for the years 2023, 2024, and 2025, respectively. The public offering consisted of 8.2258 million shares at an issue price of 16.77 yuan per share, with a price-to-earnings ratio of 14.99 times. Strategic placement shares accounted for 10% of the initial offering. The online offering saw an effective subscription volume of 51,000,517,700 shares, with an effective subscription multiple of 6,888.94 times and 714,300 valid subscribers, resulting in an online allocation rate of 0.01%. The article notes that this is a news report and does not constitute investment advice.
Read sourceN Baiji Lists on Beijing Stock Exchange, Opens Up 347% on Debut
N Baiji (stock code 920201) began trading on the Beijing Stock Exchange on September 24, 2026, with its opening price surging 347.23% to 75.00 yuan from its IPO price of 16.77 yuan. The company, which develops and sells biomedical materials, had its listing application accepted by the BSE on December 26, 2024, taking 637 days from acceptance to listing. The IPO consisted of 8.2258 million shares, with a price-to-earnings ratio of 14.99 times. The online offering saw massive demand, with an effective subscription of 51.0005 billion shares, a subscription ratio of 6,888.94 times, and a final allotment rate of just 0.01%. The company reported net profits of 50.0784 million yuan in 2023, 52.3116 million yuan in 2024, and 76.3401 million yuan in 2025. The article, sourced from Securities Times, also includes a table comparing the first-day opening performance of recent BSE-listed stocks, noting that N Baiji's 347% gain is significant but not the highest among recent listings.